随机对照试验,增加西洛斯塔,用于在 Carotid 动脉支架后的 In-Stent 缩
Hiroshi Yamagami1,2, Tomohiko Ozaki3, Kuniaki Ogasawara4
1Division of Stroke Prevention and Treatment (H.Y.), Institute of Medicine, University of Tsukuba, Japan.
Stroke
|November 25, 2024
概括
将西洛斯塔添加到抗血小板治疗中,可能会降低心脏动脉支架 (CAS) 后的内置支架缩 (ISR). 需要进一步的研究来证实对接受CAS.患者的这些发现.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 静脉静脉支架 (CAS) 后的静脉增加了缺血性中风的风险.
- 评估西洛斯塔在CAS后预防静脉静脉缩 (ISR) 的疗效对于预防中风至关重要.
研究的目的:
- 评估在接受CAS的患者中,添加西洛斯塔到抗血小板疗法对ISR的抑制作用.
- 为了比较接受西洛斯塔和未接受西洛斯塔的患者之间ISR和相关心血管事件的发生率.
主要方法:
- 一个随机的,开放的,盲目的终点试验,涉及631名患有冠状动脉狭窄症的患者.
- 患者被分配给除了其他抗血小板药物外,还可以接受胆固醇 (50或100毫克每天两次) 或没有胆固醇.
- 静脉静脉缩 (ISR) 被定义为双重超声波的最大缩速度≥1.75 m/s,随访2年.
主要成果:
- 2年内ISR的累积发病率在西洛斯塔组为10.8%,而非西洛斯塔组为19.6% (HR,0.64;P=0.056).
- 探索性分析显示,在西洛斯塔组中,超过30天的ISR发生率明显较低 (10.3%对19.3%;P=0.040).
- 两组之间没有观察到心血管事件,死亡或出血事件的显著差异.
结论:
- 将西洛斯塔添加到抗血小板治疗中,可能会降低CAS后慢性阶段的ISR.
- 这些发现表明,西洛斯塔在管理后CAS复原症方面具有潜在的益处.
- 需要使用更大的样本大小进行进一步的研究,以确认统计学意义和临床影响.
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...